How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device.
about
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.Euglycaemic glucose clamp: what it can and cannot do, and how to do it.Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.A Comprehensive Performance Evaluation of Five Blood Glucose Systems in the Hypo-, Eu-, and Hyperglycemic RangeSingle-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
P2860
Q33658772-09D2308B-64D2-4AE9-9D3F-2F168E8D6FFDQ33835638-688DC2AE-729B-4F7F-BDC8-DFD730BD08BFQ37561045-C44F30A2-B731-4910-BA5C-CBEEC66D75CCQ37575086-1ED680A4-3CC9-479D-B77D-82382549F482Q37633455-DA1DF039-FD3D-4494-9136-5D6C37ABCBDCQ38871135-30115E3F-AE9E-49AB-AECC-903346CC23A6Q39093052-93C48F4B-6451-4E9A-A525-26AC958C6CA3Q41663008-5977D6E2-6165-42E8-8CC5-FB0A931D8D6BQ44512290-88D895E3-76F9-404E-88A3-08F2C879B181Q46001828-999DEE4A-A777-43D5-B6A4-98E5B1B0520EQ47925155-8AD2B2B9-ADAF-4742-BA41-F3AF70829F02Q51240449-3FB08109-484E-42B0-AAA5-CD72DDB7691A
P2860
How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@ast
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@en
type
label
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@ast
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@en
prefLabel
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@ast
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@en
P2093
P2860
P356
P1476
How to Assess the Quality of G ...... Novel Automated Clamp Device.
@en
P2093
Carsten Benesch
Oliver Klein
Sabine Arnolds
P2860
P304
P356
10.1177/1932296815576957
P577
2015-04-07T00:00:00Z